Rafael Holdings, Inc. (NYSE:RFL) Sees Large Growth in Short Interest

Rafael Holdings, Inc. (NYSE:RFL) saw a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 121,900 shares, a growth of 26.3% from the February 28th total of 96,500 shares. Based on an average daily trading volume, of 36,200 shares, the days-to-cover ratio is presently 3.4 days. Currently, 0.6% of the company’s shares are sold short.

Institutional Trading of Rafael

An institutional investor recently raised its position in Rafael stock. Geode Capital Management LLC boosted its stake in shares of Rafael Holdings, Inc. (NYSE:RFL) by 24.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 148,068 shares of the company’s stock after buying an additional 29,448 shares during the quarter. Geode Capital Management LLC owned approximately 0.60% of Rafael worth $287,000 as of its most recent SEC filing. 11.30% of the stock is owned by institutional investors.

Rafael Price Performance

Shares of RFL traded up $0.04 during midday trading on Wednesday, hitting $1.88. The stock had a trading volume of 25,589 shares, compared to its average volume of 31,026. Rafael has a 1 year low of $1.29 and a 1 year high of $2.50. The stock’s 50 day moving average is $1.97 and its 200 day moving average is $1.92. The firm has a market cap of $46.84 million, a PE ratio of -1.13 and a beta of 1.15.

Rafael (NYSE:RFL) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.06) earnings per share (EPS) for the quarter. The firm had revenue of $0.08 million during the quarter. Rafael had a negative return on equity of 53.71% and a negative net margin of 5,707.03%.

Rafael Company Profile

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.